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ARTICLE
Unravelling the specificity and mechanism of sialic
acid recognition by the gut symbiont Ruminococcus
gnavus
C. David Owen1,7, Louise E. Tailford2, Serena Monaco3, Tanja Šuligoj2, Laura Vaux2, Romane Lallement2,
Zahra Khedri4,8, Hai Yu5, Karine Lecointe2, John Walshaw2,6, Sandra Tribolo2, Marc Horrex2, Andrew Bell2,
Xi Chen5, Gary L. Taylor1, Ajit Varki 4, Jesus Angulo 3 & Nathalie Juge2
Ruminococcus gnavus is a human gut symbiont wherein the ability to degrade mucins is
mediated by an intramolecular trans-sialidase (RgNanH). RgNanH comprises a GH33 catalytic
domain and a sialic acid-binding carbohydrate-binding module (CBM40). Here we used
glycan arrays, STD NMR, X-ray crystallography, mutagenesis and binding assays to deter-
mine the structure and function of RgNanH_CBM40 (RgCBM40). RgCBM40 displays the
canonical CBM40 β-sandwich fold and broad specificity towards sialoglycans with millimolar
binding affinity towards α2,3- or α2,6-sialyllactose. RgCBM40 binds to mucus produced by
goblet cells and to purified mucins, providing direct evidence for a CBM40 as a novel
bacterial mucus adhesin. Bioinformatics data show that RgCBM40 canonical type domains
are widespread among Firmicutes. Furthermore, binding of R. gnavus ATCC 29149 to
intestinal mucus is sialic acid mediated. Together, this study reveals novel features of CBMs
which may contribute to the biogeography of symbiotic bacteria in the gut.
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The human gut microbiota encompasses a complex com-munity of bacterial species, which play a critical role inhuman health, through their contribution to e.g., poly-
saccharide digestion, immune system development and pathogen
defence1. Microbiota composition varies longitudinally along the
gastrointestinal (GI) tract but also transversally from the lumen to
the mucosa1,2. Most gut bacteria reside in the colon, reaching
1011–1012 cells per gram, where they compete for dietary and host
glycans3,4. A dysbiosis of the gut microbiota is associated with
intestinal diseases, including cancers, infections and inflamma-
tory bowel diseases5–8, underscoring the importance of under-
standing these host-microbe interactions in order to devise novel
treatment strategies.
Several factors influence the biogeography of symbiotic bac-
teria within the gut, including the gradient and availability of
glycans within discrete physical niches2,3. The mucus layer cov-
ering the GI tract is at the interface between the gut microbiota
and the host5. In the colon, the mucus layer is divided into a loose
outer layer providing a habitat to commensal bacteria and an
inner layer adhering to the epithelium and providing protection
from bacterial invasion5. The outer mucus layer hosts a distinct
intestinal microbial niche9. The intestinal mucus layers are built
around large highly glycosylated gel-forming mucin MUC2
(Muc2 in mouse) secreted by goblet cells10. The glycan structures
present in mucins are diverse and complex and consist of four
core mucin-type O-glycans containing N-acetylgalactosamine
(GalNAc), galactose (Gal) and N-acetylglucosamine (GlcNAc).
Mucin O-glycosylation starts with the attachment of GalNAc
residues to the hydroxyl group of Ser and Thr of the protein
backbone to form the Tn antigen (GalNAcα1-Ser/Thr). This
glycan is then elongated into core 1 (Galβ1-3GalNAcα1-Ser/Thr,
also known as Thomsen Friedenreich-TF- or T-antigen), core 2
(Galβ1-3(GlcNAcβ1-6)GalNAcα1-Ser/Thr), core 3 (GlcNAcβ1-
3GalNAcα1-Ser/Thr) or core 4 (GlcNAcβ1-3(GlcNAcβ1-6)Gal-
NAcα1-Ser/Thr)11. Core 3-derived O-glycans are important
components of human colonic mucin-type O-glycans12. These
core structures are further elongated by the addition of other
carbohydrates (e.g., N-acetyllactosamine, LacNAc) and are most
commonly terminated by fucose and sialic acid sugar residues via
α1–2/3/4 and α2–3/6 linkages, respectively. These oligosaccharide
chains provide binding sites and nutrients to the bacteria which
have adapted to the mucosal environment13,14. Reflecting the
structural diversity of mucin glycans and their prime location,
commensal and pathogenic microbes have evolved a range of
adhesins allowing their interaction with mucus13,15. Variation in
mucosal carbohydrate availability leads to variations in the
composition of the resident microbiota3,16,17 and may also impact
on bacterial tropism along and across the GI tract18.
Sialic acids, such as N-acetylneuraminic acid (Neu5Ac) and
fucose residues in terminating positions on mucin glycan chains
are prominent targets for commensal and pathogenic bac-
teria19,20. The ratio of sialic acid to fucose increases along the GI
tract, from the ileum to the rectum in humans21 and an inverse
gradient occurs in mice22. Furthermore blood group Sda/Cad
related epitopes, GalNAcβ1-4(NeuAcα2-3)Gal, increase along the
length of the human colon12. Over 100 complex oligosaccharides
can be identified in mucins from human colonic biopsies, with
most being mono-, di- or trisialylated23. Release of sialic acid by
microbial sialidases allows bacteria to access free sialic acid for
catabolism, decrypt host ligands for adherence, participate in
biofilm formation, modulate immune function by metabolic
incorporation, and expose the underlying glycans for further
degradation10,14,19,20. Sialidases are often associated with addi-
tional domains including carbohydrate binding modules (CBMs),
such as sialic acid-specific CBM4014,24 and broadly specific
CBM3225. CBMs can enhance catalytic activity by concentrating
the enzymes onto carbohydrate substrates26 or mediate adherence
to host cells27.
Ruminococcus gnavus is a prominent member of the gut
microbiota of the healthy human gut28. R. gnavus utilisation of
mucin is associated with the expression of an intramolecular
trans-sialidase (IT-sialidase)29,30, which is proposed to play a key
role in the adaptation of gut bacteria to the mucosal environment
by providing 2,7-anhydro-sialic acid as a preferential source of
nutrients31. The IT-sialidase from R. gnavus (Rg) ATCC 29149
(RgNanH) comprises a catalytic glycoside hydrolase domain,
RgGH33 and a carbohydrate binding module, RgCBM40.
Here, to gain insights into the role and specificity of sialic acid
recognition by R. gnavus, we employed glycan microarray, X-ray
crystallography, saturation transfer difference nuclear magnetic
resonance spectroscopy (STD NMR), isothermal titration calori-
metry (ITC), mutational analyses, and cell/tissue binding assays
to identify RgCBM40 oligosaccharide binding partners. Promi-
nent ligands were oligosaccharides with terminal sialic acid,
including those which are not substrates for RgNanH activity. We
propose a novel role for CBM40 in targeting gut bacteria towards
sialic acid-rich regions of the GI tract.
Results
RgCBM40 belongs to the CBM40 subfamily. RgCBM40 crys-
tallised as a dimer, adopting the canonical CBM40 β-sandwich
fold with six antiparallel strands on the convex face and five on
the concave face (Fig. 1a, for data collection and refinement
statistics, see Table 1). Electron density was observed for all
RgCBM40 residues present in the construct (50–237). The sialic
acid binding site is on the concave face at the dimer interface
(Fig. 1b), however, size exclusion chromatography with multi
angle light scattering (SEC-MALS) indicated that the full-length
protein, RgNanH, is monomeric in solution (Fig. 1c). The mac-
romolecular architecture of RgCBM40 is conserved among
members of the CBM40 family (Supplementary Fig. 1), with the
exception of Vibrio cholerae CBM40_NanH (VcCBM40_NanH)
which is proposed to be part of a separate CBM40 subfamily
(Supplementary Fig. 1h)25,32. Greatest structural homology was
observed to MdCBM40 NanL (RMSD: 0.3 Å) from the Macro-
bdella decora IT-sialidase (Supplementary Fig. 1e)33.
Protein ligand complexes were achieved for both 3′SL and 6′SL
(Fig. 1d, e). No significant conformational changes were observed
in the binding site upon ligand binding. Definitive electron
density for the Neu5Ac and galactose residues was observed in
the 3′SL and 6′SL complexes. In the 6′SL complex, electron
density was also observed for the glucose residues (Fig. 1e), with
the lactose positioned almost perpendicular to the sialic acid
(Fig. 1e). Contrastingly, for the 3′SL complex, only partial
electron density was observed for the glucose residue in a single
monomer (Fig. 1d), and the glucose positioning indicates that the
lactose points up and away from the binding site, without further
interactions with the protein. In the 3′SL complex, the lactose
positioning would permit further extensions to the carbohydrate
chain as would be present in more complex or anchored glycans,
whereas these may be blocked in the 6′SL complex. This would
provide a degree of specificity towards sialic acid linkage.
Neu5Ac binds in a chair conformation (Fig. 1f, g), mimicking
the solution conformation and minimising the energetic penalty
paid upon binding26. Notably, the carboxylic acid group of
Neu5Ac forms electrostatic interactions with an arginine dyad,
Arg204 and Arg128, mimicking the coordination observed in
sialidase active sites. The C4 hydroxyl group hydrogen bonds to
Lys135 and Glu126, the N-acetyl group sits in a hydrophobic
pocket formed by Tyr116 and Ile95. The N-acetyl group nitrogen
interacts with both Glu126 and Tyr210. Glu126, Arg128 and
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Arg204 make extensive interactions with the bound ligand and
are conserved in all structurally characterised CBM40 sialic acid
binding sites, discounting VcCBM40_NanH34 (Supplementary
Fig. 2). The environment of the glycerol side-chain of sialic acid is
generally conserved across the canonical CBM40 subfamily
with the rear face (C7-H and C9-H groups) residing on a
hydrophobic surface formed by Ile95 and Tyr210 in RgCBM40
(Supplementary Fig. 3a). Although VcCBM40_NanH shares the
CBM40 β-sandwich fold (Supplementary Fig. 1), the location,
orientation, and constitution of its sialic acid binding site is not
conserved (Supplementary Fig. 2).
Structure-based sequence alignment. CBM40s associated with
sialidases fall into two subfamilies, the canonical subfamily
exemplified by CpCBM40_NanJ25 (which also regroups
RgCBM40, CpCBM40_NanI32, SpCBM40_NanA35,
SpCBM40_NanB36, SpCBM40_NanC37 and MdCBM40 NanL33),
and the Vibrio subfamily exemplified by VcCBM40_NanH34.
Considerable sequence divergence between the Vibrio and
canonical CBM40 types renders satisfactory alignments difficult
to produce with standard tools, as also previously reported32.
Here, by detailed manual inspection, paying particular attention
to the limits of secondary structure elements and intervening
loops, we produced an alignment of both types of
CBM40 sequences showing well-conserved positions along its
length, notwithstanding the Vibrio insertion (40 residues) near
the N-terminus. The pairwise identities between the canonical
representatives range from 21 to 67%, while the maximum
canonical vs. Vibrio identity is 17%, reflecting that CBM40s fall
into two distinct groups. This highlighted conserved residues
within the canonical subfamily that may be involved in binding
affinity and specificity (Fig. 2). These include (RgCBM40 num-
bering): an arginine dyad (Arg204 and Arg128) that interacts
with the sialic acid carboxylic acid group, a glutamic acid
Table 1 Data collection and refinement statistics
Data set Apo 3′SL 6′SL
Data collection
Space group P21 P21 P21
Cell dimensions
a, b, c (Å) 46.7, 72.8,
51.3
48.8, 72.4 51.5 48.7, 72.2, 51.4
β (°) 104.9 105.1 103.9
Resolution 49.56–1.73
(1.76–1.73)
39.48–1.37
(1.41–1.37)
49.91–1.30
(1.34–1.30)
Rmerge 0.03 (0.14) 0.04 (0.34) 0.03 (0.15)
I/σI 47.3 (9.6) 22.9 (3.0) 32.0 (4.9)
Completeness 91.8 (51.3) 74.5 (11.2) 83.9 (13.6)
Redundancy 3.7 (2.4) 4.3 (2.4) 5.1 (1.4)
Refinement
Resolution 49.56–1.73
(1.76–1.73)
39.48–1.37
(1.41–1.37)
49.91–1.30
(1.34–1.30)
No. of reflections 31,570 51,221 67,097
Rwork/Rfree 0.160/0.194
(0.82)
0.152/0.187
(0.81)
0.134/0.154
(0.87)
No. of atoms 3145 3424 3704
Protein 2807 2850 3076
Ligand 0 81 123
Water 338 508 527
B-factors
Protein 19.4 16.6 10.4
Ligand/ion 36.4 21.7
Water 28.1 31.7 27.3
R.m.s.d
Bond lengths
(Å)
0.011 0.012 0.015
Bond angle (°) 1.55 1.66 1.77
Values in parentheses refer to the highest resolution shell. For the 3′SL and 6′SL complexes the
data were over 90% complete to a resolution of 1.85 Å and 1.56 Å, respectively. One crystal was
used for each structure
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Fig. 1 Crystal structure of RgCBM40 in complex with 3′SL and 6′SL.
a RgCBM40 is shown in a cartoon representation with a rotation of 90°
around the x axis. b The protein crystallised as a dimer with the ligand
binding site at the dimer interface. The binding sites are shown occupied by
6′SL trisaccharides (Neu5Ac: cyan, galactose: blue, glucose: orange).
c SEC-MALS performed with full length RgNanH (77 kDa). The SEC-MALS
predicted molecular weight was 73 kDa, indicating that RgNanH is
monomeric in solution. Bound (d) 3′SL and (e) 6′SL are shown with their
corresponding Fo-Fc omit maps at 2σ (light cyan), 3σ (orange) and 5σ
(magenta). The omit maps are carved at 1.6 Å around the bound ligand. For
3′SL, the map is carved around a dummy glucose residue to indicate the
presence of partial electron density. A close-up view of RgCBM40 binding
site is shown with (f) 3′SL and (g) 6′SL. The Neu5Ac residue is shown in
cyan and the galactose residue as black lines, for clarity the glucose residue
is not shown. Interacting RgCBM40 residues are shown in green with black
dashed lines indicating hydrogen bonding interactions. A semi-transparent
surface indicates the hydrophobic surface
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(Glu126), which hydrogen bonds to the C4 hydroxyl; and a
hydrophobic surface, which accommodates the N-acetyl moiety
and the hydrophobic face of the glycerol group. Tyr116, Ile95,
Tyr210 contribute to the surface of an aromatic:aliphatic:aromatic
twisted platform which presents the glycerol hydroxyl groups to
solvent26.
Bioinformatics analyses. To gain further insights into the phy-
lotypic distribution of the CBM40 domains within bacterial
genomes, we performed a database search using pHMMs derived
from our alignment as queries (canonical and Vibrio-type toge-
ther, referred to as ‘combined’; canonical only; Vibrio-type only)
as well as Pfam models, “Sialidase(NTD)”, “Laminin_G_3”, and
“Sial-lect-inser” (see Methods section and Supplementary Meth-
ods). Our combined model successfully identified 99.9% of the
CBM40 domains matched by the individual type CBM40 models
(over 16,000 domain hits in the whole database of around 67,000
genomes). Further analysis of the data (Supplementary Methods)
led to the identification of 51 nonredundant sequences (Supple-
mentary Fig. 4). Of these, the canonical CBM40 domains
occurred in Firmicutes with 40 sequences, representing 18 genera
or pseudogenera, divided between classes Bacilli and Clostridia, as
well as Erysipelotrichi and an unclassified member of the
Firmicutes; and two sequences in Actinobacteria. The Vibrio-type
occurred only in Gammaproteobacteria, represented by
8 sequences in five genera. The separation between the Vibrio-
type sequences and canonical CBM40 sequences across bacterial
genomes was also apparent from a tree representation
constructed using a simple distance-based model and neighbour-
joining (Fig. 3). This dichotomy was fully supported by bootstrap
analysis of 1000 replicates. There was no evidence for any
intermediate or other CBM40 types. Only one sequence from
Actinobacillus muris containing a canonical CBM40 (confirmed
by pHMMs and conserved binding residues) was shown to be
part of a Gammaproteobacteria clade (all other members Vibrio-
type) as supported by 79% of bootstraps. Further studies may
indicate whether this domain is the closest to an inferred com-
mon ancestor of the canonical and Vibrio CBM40 types. The
results for co-incidence of sialidase domains clearly indicated an
association with CBM40s in this set of non-redundant sequences:
we detected a sialidase domain in 92% of canonical-type CBM40
and in all Vibrio-type CBM40 representatives.
RgCBM40 preferentially binds α2,3 linked sialosides. To fur-
ther explore RgNanH ligand specificity, RgCBM40 and inactive
mutant RgGH33 D282A, were tested for binding to various sia-
loglycans, using a slide microarray38,39. This sialoglycan micro-
array presents over 60 synthetically recreated naturally occurring
oligosaccharide structures with diverse sialic acid forms, glycosi-
dic linkages, and underlying glycans, representing a broad range
of such targets38,39. Both recombinant proteins exclusively bound
to glycans terminated with sialic acids (Fig. 4). They also showed
distinct specificities. RgCBM40 bound to most but not all glycans
bearing terminal Neu5Ac, Neu5Gc, Neu5,9Ac2 and 2-keto-3
deoxynonulosonic acid (Kdn) attached with α2-3, α2-6 and α2-8
linkages, with weaker binding for Neu5Gc and kdn oligo-
saccharides (Fig. 4). In contrast, RgGH33 D282A interacted
weakly with a narrow spectrum of sialoglycans, mainly α2-3-
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Fig. 2 CBM40 structural alignment. Structure-based alignment (α-helices and β-strands respectively in red and yellow) of CBM40 domains of RgCBM40
with C. perfringens CpCBM40_NanJ (PDB code 2V73) and CpCBM40_NanI (PDB code 5FRA), M. decora MdCBM40_NanL (PDB code 1SLI) and S.
pneumoniae SpCBM40_NanA (PDB code 4C1W), SpCBM40_NanB (PDB code 2VW0) and SpCBM40_NanC (PDB code 4YZ5) and VcCBM40_NanH
structure (PDB code 2W68). Amino acids identified as binding sites are highlighted in blue. RgCBM40 residues Ile95, Asp110, Tyr116, Glu126, Arg128,
Arg204 and Tyr210 are at positions 104, 119, 125, 135, 137, 226 and 233 of the alignment. The alignment supplemented with other canonical and
Vibrio-type CBM40 sequences, used to create the pHMM using HMMER3, is shown in Supplementary Fig. 4
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Neu5Ac-containing glycans, primarily Neu5Acα3LacNAcβ (3′
SLN), Neu5Acα3Galβ3GlcNAcβ, Neu5Acα3Galβ3GalNAc (STF),
Neu5Acα3Lacβ (GM3) and Neu5Acα3Galβ3GalNAcβ3Lac
(Fig. 4). Noticeably, RgGH33 D282A recognised some of the
α2-3-linked sialoglycans but not any α2-6- or α2-8-linked ones,
in line with its substrate specificity30. In marked contrast,
every α2-3-linked sialyl oligosaccharide present on the array
could be bound by RgCBM40. RgCBM40 showed a preference
for terminal Neu5Ac over Neu5Gc, and for α2-3≫α2-6> α2-8
linkages. RgCBM40 bound generally more strongly to glycans
containing LacNAc and Lac. RgCBM40 could bind Neu5Ac
linked Lac with α2-3 and α2-6 linkage, albeit to a lesser
degree, whereas binding to Neu5Ac linked LacNAc was
α2-3-specific. Due to the glycan orientation introduced by the
α2-6-sialic acid linkage the 6′SL glucose residue is close to the
protein surface (Fig. 1e). Therefore, α2-6-linked LacNAc N-acetyl
group may be blocked by protein residues, whereas the α2-3
linked glycan would be more solvent exposed. The highest
binding was to Neu5,9Ac2α3GalβR1. Interestingly, RgCBM40
bound to Neu5Gcα3Galβ3GalNAcβR1 (Neu5Gc-TF) and
Neu5Gc9Acα3Galβ3GalNAcβR1 (Neu5Gc9Ac-TF) although with
5–10-fold less intensity, but it could not bind to the same ligands
with the αR1 linkage. RgCBM40 bound to α2-3-sialylated Lewis X
(3′SLX, both Neu5Ac and Neu5Gc forms, although Neu5Ac was
preferred). Sulfation of the 6 position of GlcNAc in 3′SLX (both
Neu5Ac and Neu5Gc) improved binding of the protein (Fig. 4).
To validate some of the glycan array data, we used STD NMR
spectroscopy40,41 against a range of sialylated ligands. Since the
highest STD intensities correlate with the closest ligand-protein
contacts in the bound state42, STD NMR experiments provide
important information on the binding epitope of the complexed
ligand43.
Here Neu5Ac, Neu5Gc, 2,7-anhydro-Neu5Ac, 3′SL, 6′SL,
Neu5Acα3Gal (3′SGal), Neu5Acα6 Gal (6′SGal), 3′SLN, Neu5A-
cα6LacNAc (6′SLN), Neu5Gcα3Lac (3′SLGc), Neu5Gcα6Lac
(6′SLGc), Neu5Acα6GalαOC3H6N3 (Neu5Ac-STn), Neu5Gcα6-
GalαOC3H6N3 (Neu5Gc-STn) and STFαOC3H6N3 were tested
as potential ligands for RgCBM40. With the exception of the three
monosaccharides, Neu5Ac, Neu5Gc and 2,7-anhydro-Neu5Ac,
binding to RgCBM40 was detected for all di- and trisaccharides
tested. For the latter, the binding epitope mapping was obtained
and analysed as described under Methods section. Figure 5a
shows the STD NMR spectra of 3′SL and 6′SL, and Fig. 5b their
binding epitope mapping. The sialic acid ring was found to be the
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main recognition element and the binding mode was not affected
by the nature of the glycosidic linkage (α2-3 or α2-6) of the
sialoglycan (Supplementary Fig. 5). The same was true for the
other Neu5Ac-ending ligands tested (see binding epitope
mapping in Supplementary Fig. 6). The overall binding epitopes
of 3′SL and 6′SL from the STD NMR in solution state are in good
agreement with the crystal structures (Fig. 5), where the sialic acid
is in close contact to the protein surface while the lactose moiety
is solvent exposed as suggested from the very low STD intensities
observed for the galactose and glucose protons. Very strong STD
intensity were observed at the methyl group (Fig. 5). This is in
excellent agreement with the N-acetyl group sitting in the
hydrophobic pocket facing many protein protons (Hδ and Hγ)
from the side chains of Ile95, Tyr116, and Tyr210 (Fig. 1f, g).
High intensity on H7 compared to the much lower one on the
adjacent H8 agrees with H7 facing the hydrophobic side chains
while H8 (Fig. 5), in trans-conformation to it, is pointing towards
the solvent. Within experimental error, no stark differences were
observed in the orientation of the sialic acid ring in the binding
pocket of RgCBM40. RgCBM40 also showed binding to Neu5Gc-
ending oligosaccharides, albeit with a lower strength. Figure 5c
shows the binding epitope of 3′SLGc and 6′SLGc (STD spectra are
shown in Supplementary Fig. 6). Again, sialic acid was the main
recognition element of these sialoglycans, but the binding epitope
mapping was slightly different, in comparison to those of 3′SL
and 6′SL. For the Neu5Gc-ending ligands, stronger STD
intensities on H3s and lower ones on H6 were observed,
suggesting a small reorientation of the ring around C3, which
would expose C6, in order to fit the bulkier hydroxyl group on the
acetamide moiety.
The affinity of the interaction between RgCBM40 and sialic
acid ligands was further assessed by ITC. Both 3′SL and 6′SL
bound with similar low affinities, with dissociation constants of
0.57 mM and 1.70 mM, respectively (Fig. 6a, b, Supplementary
Table 1). This confirms that RgCBM40 is specific for the terminal
residue irrespective of the glycosidic linkage but with a slight
preference (~three fold) for the 2–3 linkage. Furthermore, it
would suggest that the additional binding interactions observed in
the crystal structure of the complex between RgCBM40 and 6′SL
do not significantly promote binding, also in agreement with the
STD NMR results, showing that sialic acid is the main binding
epitope in solution. We confirmed that RgCBM40 binds to
Neu5Gc-oligosaccharides, albeit with lower affinity, in accordance
with the glycan array and STD NMR results. RgCBM40 has a Kd
of ~3 mM and >10 mM towards 3′SLGc and 6′SLGc, respectively
(Fig. 6c, Supplementary Table 1). Very weak (~20 mM) interac-
tion was observed between RgCBM40 and Neu5Ac (Fig. 6d) or
Neu5Gc monosaccharides (Supplementary Table 1). The STD
NMR experiments were carried out with 1 mM sugar, well below
the Kd, which explains why no interaction was observed using
this approach. Thermodynamic analysis showed that the reaction
is enthalpy-driven (Supplementary Table 2).
To further assess the involvement of individual residues, we
introduced point mutations specifically designed to abrogate
CBM binding. Arg128, Arg204, Tyr116, Tyr210, Glu126 and Ile95
were chosen for alanine substitutions. Analysis of the secondary
structure by circular dichroism (CD) suggests that the recombi-
nant proteins were correctly folded (Supplementary Fig. 7).
Binding to Neu5Ac, 3′SL and 6′SL was abolished for the double
mutant R128A/R204A as well as all single mutants, with the
exception of I95A as shown by ITC (Supplementary Fig. 8a, b,
Supplementary Table 1). I95A binds 3′SL and 6′SL with a Kd of
1.82 and 1.37 mM, respectively, broadly similar to the binding of
the wild-type enzyme (Supplementary Table 1). This suggests that
Ile95 is not an essential component of the hydrophobic pocket or
the aromatic:aliphatic:aromatic twisted platform, and that the Tyr
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Fig. 4 Sialoglycan microarray analysis of binding specificities of RgCBM40
and RgGH33 D282A. Binding of the recombinant proteins RgCBM40 and
RgGH33 D282A at 20 and 200 µg ml−1, respectively are presented (n= 4,
SD). Heat map was generated using the method as previously
described38,39. Binding was ranked as (glycan average RFU/ maximum
glycan average RFU)×100. Red and white represent the maximum and
minimum, respectively. R1 represents propyl-azide as the spacer
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residues may compensate for the mutation of Ile95 to Ala. The
binding ability of I95A to 3′SL and 6′SL was further confirmed by
STD-NMR (Supplementary Fig. 9).
Taken together, the STD NMR and ITC data confirmed
binding of both α2-3 and α2-6 linked sugars and raise questions
regarding differences in ligand specificity between the catalytic
and carbohydrate binding domains constituting RgNanH. We
previously showed that RgNanH is specific for α2-3-linked
substrates30. To determine the influence of RgCBM40 on the
sialidase activity, we compared the enzymatic activity of RgNanH
and RgGH33 on a range of sialylated substrates. The reaction was
monitored by HPAEC-PAD and showed no difference in catalytic
activity on short oligosaccharides 3′SL, 3′SLX (Neu5Ac form) or
on large polymeric MUC2 mucins (Supplementary Fig. 10),
indicating that, in the conditions tested, RgCBM40 did not
potentiate the enzyme activity on these substrates.
RgCBM40 is a novel bacterial mucus adhesin. R. gnavus ATCC
29149 but not the E1 strain encodes the IT-sialidase required for
mucin-degradation29,30. Immunogold labelling and western
blotting confirmed the presence of RgNanH on R. gnavus ATCC
29149 cell-surface but not E1 (Supplementary Fig. 11a, b). Given
the role of RgNanH in R. gnavus mucin glycan utilisation, the
binding of RgCBM40 was tested by ELISA towards a range of
mucins with different glycosylation profiles. The sialylation level
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of purified commercial pig gastric mucin (pPGM), mixed and
Muc2/MUC2 mucins from mice and LS174T human cell line was
analysed by mass spectrometry (MS), revealing that most of the
mucins tested contained >8% sialylated structures; pPGM and
Muc2 from the colon of wild-type C57BL/6 mice contained < 2%
sialylated structures whereas the level of sialylation of LS174T
MUC2 reaches 91% (Supplementary Table 3). Highest binding
was observed to LS174T MUC2 whereas binding was lowest to
pPGM or Muc2 from the colon of wild-type mice, which contain
low levels of sialylation (Fig. 7a). The interaction was dependent
on the concentration of RgCBM40 (Supplementary Fig. 12).
RgCBM40 generally bound more strongly to mucins extracted
from C3GnT−/− mice (mutants which lack core 3 β1-3-N-acet-
ylglucosaminyltransferase, C3GnT)44 than to mucins from wild-
type mice. Irrespective of the mouse model, the binding of
RgCBM40 to Muc2 from the small intestine was higher than from
the colon (Fig. 7a). The adhesion level correlated well with the
level of sialylation between the different mucins tested (r2 = 0.88;
Fig. 7b). RgCBM40 bound significantly less strongly to MUC2
which has been treated with trifluoroacetic acid (TFA) to remove
sialic acid, or with any of the sialidases tested which included the
broad-specificity sialidase from Clostridium perfringens (Cp) and
the α2-3-specific sialidases from Salmonella typhimurium (St),
Akkermansia muciniphila (Ak) and R. gnavus (Rg), confirming
the specificity of RgCBM40 for terminal sialic acid (Fig. 7c).
Consistent with the low affinity of CBM40 for Neu5Ac, this
monosaccharide had no effect on adherence of RgCBM40 to
mucin (Fig. 7d). However, addition of free 3′SL or 6′SL prior to
binding significantly decreased adherence of RgCBM40 to MUC2
(Fig. 7d). These data indicate that RgCBM40 recognises sialylated
mammalian mucins.
Having shown that RgCBM40 can bind to sialylated oligo-
saccharides and mucins, we tested its ability to bind to mucus
from mouse intestinal tissue and human cell lines cells by
immunofluorescence (Fig. 8). Methacarn fixation allowed pre-
servation of mucus in both tissue sections and cell lines. Strong
binding was demonstrated to mucus produced by LS174T which
correlated with staining patterns of SNA (a sialic acid-specific
lectin) and MUC2 (Fig. 8a). No staining was observed in negative
controls (RgCBM40 free). RgCBM40, Muc2 and lectin staining
was also observed in crypts as well as on the epithelial surface of
mouse colonic tissue (Fig. 8b). In addition, sialidase treatment of
mouse colonic sections markedly reduced the binding of
RgCBM40, as well as the SNA lectin control (Fig. 8c). SNA can
outcompete RgCBM40 binding to the mucus layer in mouse
colonic tissue sections, further indicating that the binding of
RgCBM40 to mucus is sialic acid mediated (Fig. 8d). Similar
inhibition was observed when using bacterial cells. R. gnavus
ATCC 29149 was shown to bind to areas that correlated with
mucus staining. This binding was blocked with the addition of
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SNA (Fig. 8e), confirming the importance of sialic acid
recognition in R. gnavus ATCC 29149 binding to mucus.
Discussion
Sialic acids are often found capping mammalian glycans and are
thus common binding targets of commensal or invading
microbes. A wide variety of microorganisms utilise CBM-
containing sialidases to process these terminal sialic acid resi-
dues. At present CBMs in family 40 are the only known examples
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to bind sialic acid and are exclusively associated with sialidases
(www.cazy.org). The CBM40 from R. gnavus, RgCBM40, adopts
the characteristic CBM40 β-sandwich fold, previously reported
for CBM40s present in C. perfringens25,32, V. cholerae34, M.
decora33, as well as S. pneumoniae35–37.
In their description of C. perfringens CpCBM40_NanJ, Bor-
aston et al.25 pointed out that there appears to be two subfamilies
within the CBM40 family, one typified by CpCBM40_NanJ and
the other by V. cholerae VcCBM40_NanH. This was further
supported by phylogenetic analyses of all CBM40 structurally
characterised so far32. It is clear that Vibrio sp. forms an outlying
clade in the family that has very low amino acid sequence identity
(<15%) with the main clade32. Here, we showed that the
separation between the Vibrio-type sequences and canonical
CBM40 sequences is also observed across bacterial genomes. Both
types adopt a β-sandwich fold, however, this is the most common
core fold across CBM families26. RgCBM40 crystal structures, of
the canonical type, in complex with sialylated ligands, demon-
strate shared core binding site residues. In brief, on one side of
the sialic acid residue, the carboxylic acid and C4 hydroxyl groups
are coordinated by an arginine dyad (Arg128 and Arg204) and a
glutamic acid (Glu126) residue, respectively. The importance of
the arginine residues was further confirmed by mutational ana-
lyses, showing loss of binding of RgCBM40 R204A, RgCBM40
R128A and the double mutant RgCBM40 R128A/R204A to 3′SL.
The methyl of the N-acetyl moiety and the C-H face of the gly-
cerol moiety reside on a hydrophobic twisted platform surface
formed by primarily aromatic residues, of which Tyr116 and
Tyr210 are essential for binding. Glu126 was also shown to be
essential, as predicted given its conservation and interactions with
both the N-acetyl group N and the C4 hydroxyl of the sialic acid
moiety.
RgCBM40 showed broad specificity for sialylated oligo-
saccharides with dissociation constants to 3′SL and 6′SL in the
millimolar affinity range, 0.57 mM and 1.70 mM, respectively.
This is comparable to the affinity recently measured for the iso-
lated S. pneumoniae SpCBM40_NanC37 against 3′SL (Kd
~1.5 mM) and 6′SL (Kd ∼1.6 mM). Low sialic acid affinity has
also been proposed for CpCBM40_NanJ from the C. perfringens
sialidase however this was not quantified25. Micromolar sialic
acid affinity has been observed for C. perfringens CpCBM40_NanI
and S. pneumoniae SpCBM40_NanA32,35. Additional electrostatic
interactions with the sialic acid glycerol moiety may contribute to
these unusual affinities, in the case of SpCBM40_NanA via the
introduction of a tryptophan in place of RgCBM40 Tyr210
(Supplementary Fig. 3a, b), and in the case of CpCBM40_NanI
via Asn158, which approaches the binding site from a nearby
loop extension (Supplementary Fig. 3c). CpCBM40_NanI also
introduces additional water mediated interactions with the
galactose residues of bound 3′SL via a further loop extension
(Supplementary Fig. 1h): These are proposed to provide specifi-
city for the corresponding sialic acid linkage32. A corresponding
extension is absent in RgCBM40 leading to minimal observed
interactions between the protein and galactose (Fig.1f, g, Sup-
plementary Fig 1a). Similar absence in SpCBM40_NanA suggests
that these water-mediated interactions are not the defining fea-
ture of high CBM40 sialic acid affinity.
Overall the binding epitopes of 3′SL and 6′SL, as determined by
STD NMR, were in agreement with the crystal structure, and
confirmed the flexibility of the galactose and glucose rings at the
reducing end. Although the sialic acid moiety was the main
recognition element for the interaction with RgCBM40, only weak
binding was observed to Neu5Ac or Neu5Gc monosaccharides.
Sialic acid residues present in oligosaccharides are α-anomers.
However, in solution sialic acid adopts both α- and β-anomeric
configurations, as well as an open chain conformation, with the β-
anomer forming the dominant constituent45. In the RgCBM40
complex crystal structures, sialic acid is bound in the α-anomeric
conformation, allowing the axial C2 carboxylic acid moiety to
form a conserved interaction with Arg204. The RgCBM40 pre-
ference for the minority α-anomer will incur a large entropic
penalty. This may provide a major contributory factor to the low
observed monosaccharide affinity. Thermodynamic analysis
showed that the reaction is driven by enthalpy, with unfavourable
entropy (Supplementary Table 2), which is typical of interactions
between CBMs and saccharides46.
The binding specificity of CBMs most commonly matches that
of the appended catalytic module26,47. We previously showed that
the catalytic activity of RgNanH is specific for α2-3-linked sialic
acid30. However, our glycan array and STD NMR data clearly
showed that RgCBM40 can recognise a wide range of α2-3- and
α2-6-sialic acid-linked oligosaccharides which are commonly
found in human GI mucins12,21,23, suggesting an additional
function. More than 100 complex oligosaccharides were identified
in mucins from human colonic biopsies where most were mono-,
di- or trisialylated23. RgCBM40 bound Neu5Acα2-6Tn and
Neu5,9Ac2α2-6Tn, Neu5Acα2-3TF and Neu5,9Ac2-TF9Ac2α2-
3TF but not to the non-sialylated forms; it also recognises
Neu5Ac and acetylated Neu5Ac-linked Lac with α2-3 and α2-6
linkage but shows a strict preference for Neu5Ac-linked LacNAc
with α2-3 linkage, in line with the increased expression of group
Sd(a)/Cad related epitopes GalNAcα1-4(NeuAcα2-3)Gal along
the length of the colon12. Despite the large diversity of structures,
the sigmoid MUC2 O-glycan repertoire and relative amounts in
normal individuals is relatively constant23, suggesting their role in
selecting a specific mucus-associated microbiota. Many bacterial
species bind host tissues through protein-carbohydrate interac-
tions via a variety of cell-surface proteins and appendages.
Although a wide number of microbial lectins have been func-
tionally and structurally characterised to date, especially from
pathogens, only a few carbohydrate-binding proteins present in
gut bacteria which interact with mucus have been structurally
characterised13,15. Interactions between bacterial adhesins from
gut commensals and mucin glycans are generally of low affinity,
in line with the localisation of these bacteria within the outer
mucus layer48,49. Here we showed that RgCBM40 could recognise
Fig. 8 RgCBM40 binding to mucus-producing cells and intestinal tissue sections. a Immunostaining pattern for RgCBM40 on LS174T cells correlated with
mucin (MUC2) and lectin (SNA) staining, all shown in green. No staining was observed in RgCBM40-free sample (Blank). b Immunostaining pattern for
RgCBM40 on cryosections of mouse colon correlated with mucin (Muc2) and lectin (SNA) staining, all shown in green. No staining was observed in
RgCBM40-free sample (Blank). Cell nuclei were counterstained with DAPI, shown in blue. c Sialidase pre-treatment of mouse colonic cryosections
markedly reduced the binding of RgCBM40 and SNA lectin. Cell nuclei were counterstained with DAPI, shown in blue. d RgCBM40 competition assay with
SNA on cryosections of mouse colon. RgCBM40 is shown in green. Cell nuclei were counterstained with DAPI, shown in blue. No RgCBM40 specific
staining was detectable when SNA was present. e R. gnavus binding competition assay with SNA on cryosections of mouse colon. R. gnavus ATCC 29149
was incubated on sequential cryosections of mouse colon with or without SNA treatment and is shown in red. The mucus layer is shown in green.
Sequential sections were required as both antibodies were raised in the same species. Cell nuclei were counterstained with DAPI, shown in blue. No R.
gnavus staining was detectable when SNA was present. Appropriate primary antibody and secondary antibody only controls are also shown underneath
each panel, showing some background staining. Scale bar: 20 μm
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mucins with binding affinity increasing with sialic acid level.
Binding was highest towards human colonic MUC2, consistent
with the increasing sialic acid gradient along the GI tract from the
small intestine to the colon in humans21. This study demonstrates
CBM40 mediating interaction to mucus, therefore expanding the
repertoire of bacterial adhesins to mucus. In addition to varia-
tions along the length of the GI tract, mucin sialylation varies
significantly between species, and thus could influence host spe-
cies and niche specificity of the gut symbionts. Interestingly,
RgCBM40 also showed binding to Neu5Gc-containing oligo-
saccharides, albeit to lower affinity as compared to Neu5Ac-
oligosaccharides. Humans express predominantly Neu5Ac
whereas Neu5Gc is expressed in many non-human mammals50.
Therefore, the ability of CBM from human gut commensal bac-
teria to bind to Neu5Gc was unexpected. However, it cannot be
excluded that RgCBM40 mediates binding to dietary Neu5Gc-
containing glycoproteins51.
CBMs typically function to maintain carbohydrate-active
enzymes (CAZymes) in proximity of the substrate, thereby
enhancing catalytic activity26,46,52,53. It has recently been sug-
gested that CBMs may play an additional role in the host-
bacterium interaction by not only mediating the attachment of
CAZymes to glycans present on host tissues but by aiding the
adherence of the entire bacterium27. This would be particularly
relevant to bacteria of the human gut microbiota which are
characterised by their large and diverse repertoires of CBM-
containing CAZymes54. Many CAZymes are known, or postu-
lated to be, attached to the bacterial cell surface4. Here, immu-
nogold labelling confirmed the presence of RgNanH on R. gnavus
ATCC 29149 cell-surface but not on R. gnavus E1. In addition, we
showed that the binding of R. gnavus ATCC 29149 to intestinal
mucus was sialic acid mediated. The potential avidity effect of
CBM40-mediated binding of sialylated mucins in vivo (when
naturally present on the bacterial cell surface), may favour a
mechanism by which CBM40 helps targeting the bacteria towards
sialic acid rich regions of the GI tract, therefore promoting bac-
terial colonisation within the outer mucus layer. Our bioinfor-
matics analyses of bacterial genomes showed that RgCBM40
canonical type domains are widespread among Firmicutes, also
reflecting the strong difference in CAZyme content and diversity
between the Firmicutes and Bacteroidetes phyla54. We thus
propose a new role of CBMs in assisting the tropism and spatial
distribution of symbiotic bacteria among physical niches in the
gut.
Methods
Materials. General chemicals including Neu5Ac were from Sigma (St Louis/MOI,
US). Neu5Gcα2-3Lac Neu5Gcα2-6Lac, Neu5Ac-STn, Neu5Gc-STn and
STFαOC3H6N3) were synthesised following published methodology38,55. Neu5Gc,
3′SL, 6′SL, 3′SGal, 6′SGal, 3′SLN, 6′SLN, were from Carbosynth (Compton, Berk-
shire, UK). 2,7-anhydro-Neu5Ac was synthesised as previously reported31. Siali-
dase from Clostridium perfringens and Salmonella typhimurium LT2 were from
New England Biolabs (Ipswich, MA, USA). Sialidase 0625 from Akkermansia
muciniphila was a gift from WM de Vos30. Polyclonal antiserum against IMAC-
purified His6-RgNanH30 was raised in rabbits by BioGenes GmbH (Berlin, Ger-
many) and provided at a titre of >1:200,000. Protease inhibitors benzamidine,
N-ethylmaleimide, PMSF, sodium azide and soy bean inhibitor were from Sigma.
Fluorescein labelled Sambucus nigra lectin (SNA-FITC) biotinylated SNA (SNA-
biotin) and Vectashield were from Vector laboratories (Peterborough, UK).
Streptavidin Alexa Fluor 488 conjugate was Thermo Fischer Scientific (Eugene/OR,
USA). Deuterium oxide (99.9% 2H) and Tris(hydroxymethyl-d3)amino-d2-
methane (Tris-d11, 98% 2H) were from Sigma. Mouse monoclonal anti-His-HiLyte
Flour 555 antibody was obtained from LifeSpan BioSciences (Seattle/WA, USA).
Anti-rabbit IgG Alkaline Phosphatase (AP) conjugate antibody was from Sigma.
Blocking reagent was from Perkin Elmer (Boston/MA, USA). Rabbit Mucin 2
antibody H-300 was from Santa Cruz (Dallas/TX, US, SC-15334), goat anti-rabbit
IgG secondary antibody, Alexa Fluor 488 (A11034) and goat anti-rabbit IgG sec-
ondary antibody Alexa Fluor 594 (A11037) from Thermo Fischer Scientific. DAPI
was from Life Technologies, O.C.T. Compound from VWR and Hydromount from
National Diagnostics (Atlanta/GA, USA).
Expression and purification of RgCBM40 and RgNanH. Using the full-length
sequence encoding RgNanH in pOPINF from R. gnavus strain ATCC 29149 as a
template30, RgCBM40 (residues 50–237), RgNanH (residues 26–723) and RgGH33
(residues 243–723) were cloned into the pEHISTEV vector56 using the primers
listed in Supplementary Table 4. Protein expression and purification of RgCBM40
and RgNanH was similar to that of RgGH3330. Points of divergence are indicated
below. For protein expression, recombinant plasmids were transformed into E. coli
BL21 Rosetta (DE3) (Novagen, NJ, USA). A single colony was used to inoculate a
10 ml Luria Bertani (LB) medium pre-culture, which was incubated overnight
under shaking at 200 r.p.m. (at 30 °C for crystallisation and protein size determi-
nation or at 37 °C for all other protein assays). The pre-culture was used to
inoculate 500 ml of auto induction medium (Formedium, Norfolk, UK), which was
incubated under shaking at 37 °C for 3 h followed by 60 h incubation at 16 °C. All
cultures were inoculated with 50 µg ml−1 kanamycin.
For crystallisation and protein size determination, cells were collected by
centrifugation, resuspended in phosphate buffered saline (PBS, 150 mM sodium
chloride, 10 mM sodium phosphate, pH 7.4) for RgCBM40 and in 20 mM Tris-HCl
pH 7.5, 50 mM NaCl for RgNanH, supplemented with DNase I (20 µg ml−1) and
cOmplete protease inhibitor mixture tablets (Roche, Welwyn Garden City, UK),
and lysed using a constant flow cell disrupter. Insoluble components were removed
by centrifugation and filtration through a 0.22 µm pore size syringe driven filter
(Millipore, NJ, USA). Soluble lysate was loaded onto a nickel-Sepharose column
(GE Healthcare, Little Chalfont, UK) overnight at 4 °C. The sample was then
washed extensively with lysis buffer supplemented with 5 mM imidazole for
RgCBM40 and with 150 mM imidazole for RgNanH and was eluted using lysis
buffer supplemented with 50 mM imidazole for RgCBM40 and with 300 mM
imidazole for RgNanH. The sample was then dialysed into lysis buffer and cleaved
of its six-histidine tag using in-house Tobacco Etch Protease at a mass ratio of 1:50
overnight at 4 °C. Finally, the gel filtration step using a Sephacryl S-100 column
(GE Healthcare) was performed using 20 Tris, pH 7.5 with 50 mM NaCl. The
purified RgCBM40 was crystallised as described below. To determine the size in
solution of RgNanH, size exclusion chromatography with multi angle light
scattering (SEC-MALS) was performed using an NGC chromatography system
(Biorad, Hercules, CA, USA) equipped with a DAWN HELEOS II MALS detector
(Wyatt technology, Haverhill, UK) and an Optilab T-rEX differential Refractive
Index detector (Wyatt Technology). The data were analysed using ASTRA (Wyatt
Technology).
For all other protein assays, the cell pellets were resuspended in Bug buster-HT
(Merck, Kenilworth, NJ, USA) with the supplied lysozyme and lysed by shaking in
this solution for 1 h at room temperature. Insoluble material was removed by
centrifugation at 4 °C, 3320×g for 25 min and the supernatant was dialysed into
desalting buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.8 containing 10 mM
imidazole for RgGH33 and RgNanH and no imidazole for RgCBM40, the difference
is due to the poor binding of the His6-tag of RgCBM40 to the nickel column) to
remove the Bug buster-HT. Again insoluble material was removed by
centrifugation as above, except at 8000×g. Purification of the soluble lysate was
loaded onto the immobilised metal ion affinity chromatography (IMAC column,
His-bind, Novagen) in binding buffer (desalting buffer with the addition of 10 mM
imidazole) using the Akta Express (GE Healthcare). The protein was eluted with
binding buffer containing 500 mM imidazole and then immediately desalted into
desalting buffer. The partially purified protein was concentrated using 3.5 kDa
MWCO spin columns (Sartorius, Gottingen, Germany) prior to gel filtration again
with the Akta Express in desalting buffer (see above) on a Superdex 75 column (GE
Healthcare). Purity of the proteins was assessed throughout by SDS-PAGE using
the Novex system (Thermo Fisher Scientific).
Site-directed mutagenesis. Site directed mutagenesis of RgGH33 to introduce the
D282A mutation in the active site was carried out using the QuikChange kit,
following the manufacturer’s instructions, Agilent (Santa Clara, CA, USA). Site-
directed mutants of RgCBM40; I95A, Y116A, E126A, R128A, R204A and double
mutant R128A/R204A, were obtained from NZyTech (Lisbon, Portugal). The
primers are listed in Supplementary Table 4. The integrity of the RgGH33 and
RgCBM40 mutants was checked by circular dichroism (CD).
Circular dichroism. CD spectra were recorded using a JASCo J-700 spectro-
polarimeter, under the following conditions: 20 nm/min scan speed, bandwidth
1 nm, response 2 s, 5 points/nm and 4 accumulations. Far-UV spectra (260-
180 nm) were recorded in a 0.1 mm pathlength cell. The spectropolarimeter was
calibrated using camphorsulphonic acid (Sigma). The protein was extensively
dialysed into 10 mM sodium phosphate buffer, pH 6.5 and a buffer only control
was subtracted from all spectra using the molar CD factor calculated as follows:
(113 × 30 × 10−6)/ [conc(mg ml−1)×pathlength (cm)].
Protein crystallisation. The final crystallisation condition was 0.2 M ammonium
chloride with 20% PEG 8000. The drop contained 0.5 µl protein solution at 25 mg
ml−1 and 0.5 µl reservoir solution, initial crystals grew in 4 weeks and growth time
was improved significantly using micro seeding57. Crystals were cryoprotected
using the crystallisation condition supplemented with 25% (w/w) glycerol. To
achieve crystal structures in complex with 3′SL and 6′SL, the crystals were grown in
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crystallisation condition supplemented with 20 mM ligand followed by a 60 min
soak in crystallisation condition supplemented with 100 mM ligand immediately
prior to cryoprotection and mounting.
Solving the crystal structure. X-ray diffraction experiments were performed at
100 K. Data were collected using a Rigaku MSC Micromax 007 HF X-ray source,
with a fixed wavelength of 1.542 Å, and a Saturn 944+ CCD detector. Sweeps were
indexed and integrated separately and then scaled together within the HKL2000
data processing package58. Phasing was performed by Phaser59 within the CCP4
package60 using the CBM40 of the M. decora sialidase NanL (MdCBM40_NanL)
(PDB 2SLI)33 as the molecular replacement model. The model was refined using
iterative cycles of Refmac561 and Coot62. The PDB REDO server was used to
optimize the refinement parameters63. The model was validated using the Mol-
probity server64. Paired refinement performed by the PDB REDO server indicated
that the models were improved by the inclusion of high resolution, low com-
pleteness data for the 3′SL and 6′SL complexes65. For an illustrative stereo image of
a portion of the electron density map, see Supplementary Fig. 13.
Isothermal titration calorimetry. Isothermal titration calorimetry (ITC) experi-
ments were performed using the PEAQ-ITC system (Malvern, Malvern, UK) with a
cell volume of 200 µl. Prior to titration protein samples were exhaustively dialysed
into PBS. The ligand was dissolved in the dialysis buffer. The cell protein con-
centration was 115 µM (except for mutant I95A where it was 173 µM and the wild-
type interaction with 6′SL where it was 230 µM) and the syringe ligand con-
centration was 10 mM (25 mM for Neu5Ac). Controls with titrant (sugar) injected
into buffer only were subtracted from the data. Analysis was performed using
Malvern software, using a single-binding site model. The stoichiometry of binding
sites was set to 1.0 as this was evident from the crystal structure. Quantitative and
most qualitative experiments were carried out in triplicate.
STD NMR experiments. 1H and 13C resonance assignment for all the sugars was
performed on the bases of 1D 1H, 2D DQF-COSY, TOCSY, HSQC and NOESY
experiments run on the free ligands in unbuffered D2O, pH 7.0. For STD NMR
experiments, all the samples consisted of 1 mM sialoglycans and 50 μM RgCBM40
(WT or I95A mutant) in D2O buffer solution of 10 mM Tris-d11 pH 7.8 and
100 mM NaCl (ligand: protein ratio 20:1). An STD pulse sequence that included
2.5 ms and 5 ms trim pulses and a 3 ms spoil gradient was used. Saturation was
achieved applying a train of 50 ms Gaussian pulses (0.40 mW) on the f2 channel, at
0.60 p.p.m. (on-resonance experiments) and 40 p.p.m. (off-resonance experiments).
The broad protein signals were removed using a 40 ms spinlock (T1ρ) filter. All the
experiments were recorded at 1H frequency of 800.23 MHz on a Bruker Avance III
spectrometer equipped with a 5 mm probe TXI 800 MHz H-C/N-D-05 Z BTO, at
288 K. For all the sialoglycans in the presence of RgCBM40, an STD experiment
with a saturation time of 2 s and a relaxation delay of 5 s was performed, as a first
test for binding. For the confirmed binders, the STD NMR experiments were
carried out at different saturation times (0.5, 1, 2, 3, 4 and 5 s) with 1 K scans and
relaxation delay of 5 s, in order to obtain the binding epitope mapping. The
resulting build-up curves for each proton were fitted mathematically to a mono-
exponential equation (y = a×[1-exp(b×x)]), from which the initial slopes (a×b)
were obtained. For each ligand, the binding epitope mapping was obtained by
dividing the initial slopes by the one of the H7 proton of the corresponding sialic
acid ring, to which an arbitrary value of 100% was assigned. This normalisation of
the STD values allows the comparison across all the sialoglycans.
Structure-based sequence alignment and bioinformatics analyses. A structural
alignment of RgCBM40 was carried out with all CBM40 structures available to date
(Results and Supplementary Methods). This served as a basis for producing an
alignment including both canonical and Vibrio-type CBM40 sequences to create a
profile Hidden Markov Model (pHMM) using the HMMER3 software (http://
hmmer.org/) (Supplementary Fig. 14), intended to detect both types simulta-
neously and ensure that hit sequences of both types are thus properly aligned for
subsequent comparative analysis. Additionally, we created pHMMs corresponding
to the canonical-only and Vibriotype-only CBM40 sequences of this alignment, to
resolve the type of each hit. Protein domain databases such as Pfam66 currently
characterise the canonical CBM40 as a sequence family belonging to a larger
superfamily (“clan”), and some individual domains make good matches to more
than one related family, i.e., including non-CBM40 such as “Concanavalin A-like
lectin/glucanases” (in contrast, no Pfam domain clearly defines the Vibrio CBM40).
We therefore also used the corresponding Pfam pHMMs, as well as our own, to
search all available (177 million) protein sequences from annotated NCBI pro-
karyote genomes, using HMMER3. Where individual hit domains matched mul-
tiple pHMMs, we compared scores to identify and discard hits which might be
better regarded as related, non-CBM40 domains. The remaining CBM40 proteins
were screened for the presence of the sialidase domain (GH33), as previously
described30. We reduced this to a nonredundant set (Supplementary Methods) for
further analysis. A detailed phylogenetic analysis is beyond the scope of this study,
but we estimated evolutionary distances between these 51 representative sequences
using fprotdist in EMBASSY-PHYLIP67,68 from which the tree was calculated by
neighbour-joining (fneighbor). All sites were included in the analysis, using the
PMB model with a uniform rate of evolution. This was repeated on 1000 replicate
datasets produced by bootstrap resampling (fseqboot; consensus tree produced by
fconsense). The figure was produced with FigTree (http://tree.bio.ed.ac.uk/
software/figtree/). Bioinformatics analyses were performed using the Gut Health
and Food Safety Linux servers at Quadram Institute Bioscience.
Glycan microarray screening. Glycan microarrays were fabricated using epoxide-
derivatized slides as previously described38. Printed glycan microarray slides were
blocked by ethanolamine, washed and dried. Slides were then fitted in a multi-well
microarray hybridisation cassette (AHC4X8S, ArrayIt, Sunnyvale, CA, USA) to
divide into 8 subarrays. The subarrays were blocked with ovalbumin (1% w/v) in
PBS (pH 7.4) for 1 h at room temperature, with gentle shaking. Subsequently, the
blocking solution was removed and diluted protein samples of RgCBM40 and
RgGH33 D282A with various concentrations were added to each subarray. After
incubating the samples for 2 h at room temperature with gentle shaking, the slides
were washed. Diluted anti-His-HiLyte Flour 555 antibodies in PBS were added to
the subarrays, incubated for 1 h at room temperature, washed and dried. The
microarray slides were scanned by Genepix 4000B microarray scanner (Molecular
Devices Corp., Union City, CA, USA). The data analysis was performed using
Genepix Pro 7.0 analysis software (Molecular Devices Corp.). It is important to
note that glycans on the array with sialic acid O-acetyl groups undergo gradual
losses of these labile ester groups. Therefore, definitive conclusions about 9-O-
acetylation are only possible in instances wherein binding is exclusively to the O-
acetylated sialoglycan spot, and not to the corresponding non-O-acetylated spot.
RgCBM40 binding to mucus-producing cells. The binding of RgCBM40 to
mucus-producing LS174T cell line (80% confluent, passage 12) was performed by
incubating the cells with 150 µg ml−1 RgCBM40 in cell culture medium for 2 h at
37 °C. Control samples were incubated with cell culture medium only. The cells
were then washed with PBS, fixed in methacarn (60% dry methanol, 30%
chloroform and 10% acetic acid) and washed in PBS containing 0.05% bovine
serum albumin (BSA). Blocking was done with TNB buffer (0.5% w/v blocking
reagent in 100 mM Tris-HCl, pH 7.5, 150 mM NaCl) supplemented with 5% goat
serum. The RgCBM40 binding was detected with custom-made rabbit RgNanH
antiserum diluted 1:100 in PBS and goat anti-rabbit antibody diluted 1:400 in PBS.
The same antibodies were used for negative control sample (RgCBM40-free). In the
lectin control sample, SNA-biotin (incubated at 75 µg ml−1) was detected with
streptavidin conjugate (2.5 µg ml−1). MUC2 was detected with rabbit Mucin 2
antibody diluted 1:50 in PBS and goat anti-rabbit antibody diluted 1:200 in PBS.
The cells were counterstained with DAPI and mounted in Vectashield. The slides
were imaged using a Zeiss Axio Imager 2 microscope.
RgCBM40 and R. gnavus binding to intestinal tissue. To assess the binding of
RgCBM40 to intestinal tissue sections, colon of wild-type C57BL/6 mouse was
washed with PBS, fixed in methacarn, embedded in O.C.T. compound and cut into
8 µm sections. Access to mouse tissues was carried out under the Animal Welfare
and Ethical Review Body of University of East Anglia's establishment licence
(according to Home Office requirements). Tissue sections were washed in PBS
containing 0.05% BSA and blocked with TNB buffer (0.5% w/v blocking reagent in
100 mM Tris-HCl, pH 7.5, 150 mM NaCl) supplemented with 5% goat serum. The
slides were then washed in PBS 0.05% BSA, followed by 2 h incubation of 150 µg ml
−1 RgCBM40 in PBS at 37 °C. Control tissue sections were incubated in PBS only.
After washes in PBS with 0.05% BSA, the binding of RgCBM40 was detected with
custom-made rabbit RgNanH antiserum (diluted 1:100 in TNB buffer) and goat
anti-rabbit antibodies (diluted 1:200 in PBS). Negative control sample (RgCBM40-
free) was also incubated with these primary and secondary antibodies. Muc2 was
detected with Mucin 2 antibody diluted 1:100 in TNB buffer and goat anti rabbit
antibody diluted 1:200 in PBS. In lectin controls SNA-FITC was incubated at 4 µg
ml−1. The sections were counterstained with DAPI and mounted in Hydromount
mounting medium. The slides were imaged using an Axio Imager 2 Zeiss micro-
scope. To assess the binding specificity of RgCBM40 to sialylated structures, the
tissue sections were pre-treated with sialidase. Briefly, saponification was per-
formed to make the enzymatic digestion of mouse colonic tissue sections effec-
tive69. The sections were treated with 0.5% KOH in 70% ethanol for 15 min at
room temperature. After three PBS washes, 500 Uml−1 sialidase from Clostridium
perfringens in GlycoBuffer 1 (New England Biolabs) was added and incubated for
14 h at 37 °C. Sections were incubated in sialidase-free GlycoBuffer 1 under the
same experimental conditions and used as a control of sialidase digestion to assess
the binding of RgCBM40 and SNA to tissue sections as described above.
To assess the binding of R. gnavus to intestinal tissue sections, colon of wild-
type C57BL/6 mouse was washed with PBS, fixed in methacarn, embedded in O.C.
T. compound and cut into 12 µm sections. Tissue sections were washed in PBS,
then incubated with SNA in PBS at 20 μg ml−1 for 1 h. Prior to incubation with
bacteria, the slides were washed with PBS. R. gnavus ATCC 29149 was cultured
anaerobically in BHI-YH media for 24 h as previously described29. The culture was
then then used to inoculate YCFA media supplemented with 3′SL at a
concentration of 7 mgml−1, and cultured for 20 h. The bacteria were then washed
twice with fresh YCFA, and resuspended at an OD of 1. The tissue sections were
then transferred in a humid chamber to the anaerobic cabinet, and the bacteria
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incubated on the sections for 1 h at 37 °C. The slides were then washed twice with
YCFA and fixed with 4% paraformaldehyde in PBS for 15 min. The slides were
transferred out of the anaerobic cabinet, then washed with PBS and blocked with
TNB buffer (0.5% w/v blocking reagent in 100 mM Tris-HCl, pH 7.5, 150 mM
NaCl) supplemented with 5% goat serum. The presence of R. gnavus and Muc2 was
detected with custom-made rabbit RgNanH antiserum (diluted 1:100) and Mucin 2
antibody (1:100), respectively. Goat anti-rabbit antibodies (diluted 1:500) were used
for immunodetection. The sections were counterstained with DAPI and mounted
in Prolong gold anti-fade mounting medium. The slides were imaged using an Axio
Imager 2 Zeiss microscope, using a ×63 objective.
Mucin purification. Culture media from LS174T cell line were freeze-dried before
extraction of MUC2. After freeze-drying, samples were solubilised overnight in 6 M
guanidine chloride (GuCl) buffer containing protease inhibitors (7.95 mM EDTA,
12.25 mM benzamidine, 6.25 mM N-ethylmaleimide, 1.25 mM PMSF, 3.75 mM
sodium azide, 0.1 mgml−1 soy bean inhibitor). Samples were centrifuged at 18
500×g. The pellet was reduced with dithiothreitol (DTT) at 10 mM for 4 h at 45 °C
and alkylated with 25 mM iodoacetamide overnight before dialysis against 50 mM
ammonium bicarbonate. The same protocol was followed for purifying mucins
from the scraped mucus from small intestine and colon of mouse models. The
supernatants containing soluble mucins were diluted in 4M guanidinium chloride
(GuCl) with phosphate buffered saline (PBS) and adjusted with cesium chloride at
1.4 g ml−1 density. Supernatants were subjected to an ultracentrifugation (Beck-
man, Brea, US) at 234,000×g for 72 h at 20 °C. Fractions of 1 ml were collected and
weighed. Fractions between 1.35 and 1.45 g ml−1 were kept and dialysed against
50 mM ammonium bicarbonate. These fractions contained the purified mucins.
Release of oligosaccharides from mucin. The mucins were subjected to β-
elimination under reductive conditions (0.1 M sodium hydroxide, 1 M sodium
borohydride) for 20 h at 45 °C. The reaction was stopped by adding Dowex 50 × 8
(Sigma) and filtered before being co-evaporated with methanol 3 times. Remaining
salts were removed by Carbograph (Grace, Columbia, USA).
Permethylation of O-glycans. Permethylation was performed on released
O-glycans from the different mucins samples. Samples were solubilized in 200 μl
dimethyl sulfoxide. Then sodium hydroxide (trace of powder) and 300 μl iodo-
methane were added in anhydrous conditions and the samples vigorously shaken at
room temperature for 90 min. The permethylation reaction was stopped by addi-
tion of 1 ml acetic acid (5% vol/vol). Permethylated O-glycans were purified on a
Hydrophilic-Lipophilic Balanced (HLB) Oasis cartridge (Waters, Milford, USA).
Briefly, cartridges were activated by methanol, equilibrated with methanol:water
(5:95, vol:vol), and samples loaded onto the cartridges. Cartridges were washed by
methanol:water (5:95, vol:vol) and the permethylated O-glycans eluted by
methanol.
Analysis of permethylated O-glycans by mass spectrometry. MALDI-TOF and
TOF/TOF-MS data were acquired using the Bruker Autoflex analyzer mass spec-
trometer (Applied Biosystems, Foster City, CA, USA) in the positive-ion and
reflectron mode by using 2,5-dihydroxibenzoic acid (DHB; Sigma; 10 mgml−1 in
70:30 methanol:water) as the matrix. The relative quantification of sialylation on
mucins was calculated based on the sum of all areas of mass peaks corresponding
to sialylated structures divided by the sum of all areas of mass peaks corresponding
to defined O-glycans.
Enzyme linked immunosorbent assay. RgCBM40 binding to purified mucins was
tested by ELISA. Mucins (100 μl of 10 μg ml−1) were immobilised onto a high
binding 96 well plate (Greiner, Stonehouse, UK) overnight at 4 °C. All subsequent
steps were carried out for 1 h at room temperature. The plates were blocked with
3% (w/v) BSA, incubated with RgCBM40 (500 μg ml−1), followed by an incubation
with 1:5000 anti-RgNanH (raised in rabbit, Biogenes) then with 1:5000 anti-rabbit
secondary antibody (raised in donkey) conjugated to peroxidase (GE Healthcare).
Between each step, the plate was washed with 3 × 300 μl of PBS containing 0.05%
(v/v) Tween 20 (PBST). Prior to detection, an additional wash step and 30 s
incubation with PBST was carried out. Binding was detected using tetra-
methylbenzidine (TMB) visualisation solution (Biolegend, San Diego, CA, USA)
which was incubated for 15 min. The reaction was stopped by addition of 2 M
H2SO4 and absorbance measured at 450 nm using a plate-reader (Bench Marl Plus,
Biorad), subtracting background readings at 570 nm. Negative controls including
no RgCBM40 (subtracted from A450 value), no primary or no secondary antibody
were carried out in parallel. For comparison between plates, values were normal-
ised to the reading for LS174T MUC2 which was arbitrarily set at 100%. For
enzymatic treatment of the mucin, LS174T MUC2 (2 mgml−1) was incubated with
sialidases (2 µg ml−1) overnight at 4 °C on a rotary wheel prior to immobilisation
on the plate. For chemical treatment of mucin, LS174T MUC2 was incubated with
0.1 M trifluoroacetic acid (TFA) at 80 °C for 1 h, dialysed against ammonium
bicarbonate (50 mM), lyophilised and redissolved in H2O. For the competition
assays, RgCBM40 was incubated with 1 mM of free sugar overnight at 4 °C on a
rotary wheel prior to addition to the ELISA plate as above. Experiments were
carried out in triplicate.
HPAEC-PAD analyses. The substrates, 3′SL (500 μM, 8.5 nM enzyme), 3′SLX
(Neu5Ac form), (500 μM, 80 nM enzyme) or LS174T MUC2 (0.9 mgml−1, 1.5 nM
enzyme) were incubated with RgNanH or RgGH33 at 37 °C in 20 mM sodium
phosphate buffer, pH 6.5. BSA (0.1 mgml−1) was included in the oligosaccharide
reactions. Control reactions without enzyme were also carried out in parallel.
Aliquots of reaction were removed and the reaction terminated by boiling for
20 min. For LS174T MUC2, the released sugars were removed using 5 kDa MWCO
spin columns and the remaining mucin subjected to acid hydrolysis; the samples
were incubated with 0.1 M HCl at 80 °C for 1 h, dried under vacuum and resus-
pended in H2O at 1 mgml−1. The amount of Neu5Ac remaining on the mucin was
quantified by comparing the peak size for Neu5Ac with an internal standard of 2-
keto-3-deoxynononic acid (Kdn). The reaction products for all substrates were
filtered with 0.22 μm spin tubes prior to analysis by HPAEC-PAD (Dionex ICS-
5000, Thermo Fisher Scientific). An internal standard of fucose (50 μM) was used
for 3′SL and 3′SLX. For 3′SL, a Carbo-Pac PA1 column (Thermo Fisher Scientific)
was used with a 6 min isocratic gradient of 100 mM sodium hydroxide, 100 mM
sodium acetate followed by a 10 min washing step with 100 mM sodium hydroxide,
200 mM sodium acetate and 10 min re-equilibration with 100 mM sodium
hydroxide, 100 mM sodium acetate. For 3′SLX, a Carbo-Pac PA100 was used with
5 min at 100 mM sodium hydroxide, a gradient of 0–50 mM sodium acetate over
5 min, followed by a gradient of 50–225 mM sodium acetate. The column was then
cleaned with 500 mM sodium acetate for 5 min and re-equilibrated for 15 min at
100 mM sodium hydroxide. For analysis of the acid hydrolysis products of MUC2,
a Carbo-Pac PA10 was used with a gradient of 70–300 mM sodium acetate with
100 mM sodium hydroxide over 10 min, a brief (1 min) period of 300 mM sodium
acetate followed by a decrease (over 1 min) to 70 mM sodium acetate and 15 min
re-equilibration at 70 mM sodium acetate. All columns were protected with their
respective guard columns, except for the mucin analysis where an amino-guard
column was used.
Western blotting. R. gnavus strains were grown to stationary phase and cells
pelleted by centrifugation for 10 min at 3000×g at 4 °C. The supernatant was
collected and the extracellular proteins concentrated 50-fold using a 10-kDa
MWCO Amicon Ultra-0.5 Centrifugal Filter (Millipore, Watford, UK). The cell
pellet was resuspended in 20 μl PBS with an equal bead (100 μm glass beads)
volume added and samples vortexed at full speed three times for 2 min with 2 min
rest intervals on ice. The volume was made up to 17 μl per mg wet cell weight with
PBS and vortexed at full speed again for 2 min. The beads were removed by
allowing them to settle under gravity and the remaining samples centrifuged for
30 min at 17,000×g at 4 °C. The supernatant containing the soluble cytosolic
proteins was collected and concentrated 10-fold using a 10-kDa MWCO Amicon
Ultra-0.5 Centrifugal Filter. The remaining pellet was dissolved in 1.7 μl per mg wet
cell weight digestion buffer (50 mM Tris-HCl, (pH 8.0), 5 mMMgCl2, 5 mM CaCl2,
10 mgml−1 hen egg white lysozyme (Sigma)), and incubated at 37 °C for 3 h. The
samples were centrifuged for 30 min at 17,000×g at 4 °C, and the supernatant
containing the cell wall associated proteins collected. Samples were analysed on
duplicate on NuPAGE Novex 4–12% Bis-Tris gels, one gel was stained with
InstantBlue stain (Expedeon, Swavesey, UK) and the other gel blotted onto a PVDF
membrane using X-cell II Blot module (Thermo Fisher Scientific), according to
manufacturer’s instructions. Membranes were blocked with 3% BSA in PBST for
3 h, and then incubated with the custom-made anti-RgNanH antibody raised in
rabbit diluted 1:5000 in 1% BSA in PBST overnight. Blots were washed in PBST,
then incubated with anti-rabbit IgG AP-conjugate antibody (Sigma) diluted 1:7500
in 1% BSA in PBST for 2 h. After washing three times in PBST, the blots were
incubated using a visualisation solution (10 ml of 0.1 M Tris-HCl (pH 9.6), 40 μl of
1 M MgCl2, 20 μl of nitroblue tetrazolium, and 10 μl of 5-Bromo-4-Chloro-3-
Indolyl phosphate, Sigma) for up to 15 min, and washed in distilled water to stop
the development of the signal.
Immunogold labelling of whole bacterial cells. R. gnavus strains were grown to
stationary phase and cells pelleted by centrifugation for 10 min at 3000×g at 4 °C
before being resuspended in PBS. A small drop of concentrated R. gnavus cell
suspension was applied to a formvar/carbon coated gold TEM grid (Agar Scientific,
Stansted, UK) and left for 1 min. The bacteria on the grids were vapour fixed by
placing the grids in a sealed Petri dish with a small cap-full of 25% glutaraldehyde
(Agar Scientific) for 2 h. The grids were floated on drops of 50 mM Glycine/PBS for
15 min followed by floating on drops of Aurion blocking buffer (Aurion,
Wageningen, The Netherlands) for 30 min. The grids were then washed five times
for 5 min with 0.1% BSA-C (Aurion) in PBS. Grids were incubated in anti-RgNanH
antibody raised in rabbit diluted 1:2000 with 0.1% BSA-C/PBS or in a control
solution of 0.1% BSA-C/PBS overnight at 4 °C. The grids were washed five times
for 5 min with 0.1% BSA-C/PBS. Grids were then transferred to a 1/50 dilution of
goat anti-rabbit antibody conjugated with 10 nm gold balls (Agar Scientific) in
0.1% BSA-C/PBS and incubated for 2 h at room temperature. The grids were
washed five times for 5 min with 0.1% BSA-C/PBS, followed by three 5 min washes
in PBS only. The grids were refixed by immersing them in 2% glutaraldehyde/PBS
for 1.5 h followed by three 5 min PBS washes and three 5 min distilled water washes
before the grids were carefully blotted and dried. The grids were examined and
imaged in a FEI Tecnai G2 20 Twin transmission electron microscope at 200 kV.
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Statistical analysis. One-way ANOVA model analyses were used to assess the
binding of RgCBM40 to purified mucins by ELISA. When the effect of the factor
was found to be significant (p value< 0.05) and its number of levels greater than 2,
a Tukey test was used to assess the significance of the difference between multiple
means. Statistical analyses were performed using the software SAS 9.4 (NC, USA).
Data availability. Atomic coordinates have been deposited in the Protein Data
Bank (www.rcsb.org) with accession codes: 6ER2 (unbound), 6ER3 (3′SL bound)
and 6ER4 (6′SL bound). The data that support the findings of this study are
available from the corresponding author upon request.
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